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Osteoarthritis (OA) is characterised by gradual destruction of articular cartilage and leads to painful 
and dysfunctional knee-, hip- or hand-joints. With the increasing life expectancy and obesity, the 
prevalence is expected to rise. In the younger population, joint pain and disability can result from local 
cartilage defects resulting from injury or disease. After the introduction of autologous chondrocyte 
implantation (ACI) as a treatment option for localised cartilage defects in the late 80’s, cell‑based 
repair techniques have been extensively explored through clinical trials aiming to improve long‑term 
clinical outcomes. However, the role of ACI remains that of postponing joint replacement in patients 
with localised defects, and despite persistent research on cartilage repair strategies, there is no 
available treatment to halt or reverse the degenerative process of OA once initiated. The focus of this 
thesis has thus been to gather new basic knowledge on cartilage functions in the context of cell 
signalling receptors. 
In the first study, we have explored the effects of the powerful inflammatory mediator leukotriene B₄ 
(LTB₄) on human articular chondrocytes based on studies indicating that this mediator could hold a 
key role in inflammatory joint diseases. When cyclooxygenase (COX) inhibitors are prescribed to 
reduce inflammation and pain e.g. in patients with OA, there is a shunting from the prostaglandin- to 
the leukotriene axis with subsequent upregulation of LTB₄. We demonstrated that chondrocytes 
express both the high‑affinity (BLT1) and the low‑affinity (BLT2) LTB₄ receptors by 
immunolabelling and gene expression. By Western blot, we showed that the high‑affinity BLT1 
receptor is active. Upon stimulation of chondrocyte cultures by the ligand, we found no effect on 
biological functions such as release of inflammatory mediators, proliferation, cartilage gene 
expression or matrix formation. The overall results suggest that the leukotriene axis is not very active 
in cartilage, and that the role seen in other inflammatory diseases is probably linked to the ability of 
LTB₄ to recruit neutrophils, a mechanism that is less prominent in osteoarthritis pathology. 
In the second paper, we investigated the influence of the active hormonal form of vitamin D, 
1α,25(OH)₂D₃, on chondrocyte functions and evaluated potential modulating effects on inflammation 
as suggested by clinical studies showing improved pain scores after vitamin D supplementation. By 
immunolabelling and gene‑expression, we found that the expression of vitamin D receptor (VDR) in 
native cartilage is elusive, but that receptor expression increase upon dedifferentiation and during 
inflammatory conditions. We also demonstrated that 1α‑hydroxylase, the enzyme catalysing the 
conversion of 25(OH)D₃ to 1α,25(OH)₂D₃, is expressed in cartilage and that the expression persists 
through cellular dedifferentiation and redifferentiation. In monolayer cultures the 25(OH)D₃ was 
converted to 1α,25(OH)₂D₃ in a dose dependent matter, and exposing chondrocytes to both 25(OH)D₃ 
and 1α,25(OH)2D increased their proliferation rate. The proteoglycan genes ACAN and VCAN 
displayed an inverse expression pattern, and matrix production was diminished in chondrocytes treated 
with 25(OH)D₃ or 1α,25(OH)₂D₃. The results imply that cartilage can contribute to the increased level 
of 1α,25(OH)₂D₃ seen in synovial fluid of OA patients, but 25(OH)D₃ or 1α,25(OH)₂D₃ may only 
exert effects on chondrocytes upon dedifferentiation or during inflammatory conditions. 
The third paper aimed at identifying biomarkers of intrinsic chondrogenic potential in chondrocyte 
cultures established from 17 donors undergoing ACI treatment. Patient‑derived chondrocytes cultures 
were grouped according to their chondrogenic abilities in scaffold‑free 3D cultures, as evaluated by 




molecules and growth factor receptors were measured using flow cytometry or gene expression. The 
gene expression of TGF‑β receptor 3 was inversely related to chondrogenic potential, while all other 
molecules tested had a uniform expression pattern among all donors. A global proteomic profiling of 
cell‑associated proteins using tandem‑mass‑tag technology pointed at prolyl 4‑hydroxylase, a pivotal 
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Definitions of key concepts 
Bern score 
The Bern score is a visual histological scoring and accounts for uniformity and intensity of matrix 
staining, cell density/ECM ratio and cellular morphology. 
 
Cell adhesion molecules 
Cell‑surface molecules, usually glycoproteins, which mediate cell‑cell and cell‑matrix interactions and 
thus maintain tissue integration. 
 
Cell differentiation 
Progressive restriction of the developmental potential and increasing specialization of function that 
leads to the formation of specialised cells, tissues, and organs. 
 
Cell dedifferentiation 
A reverse developmental process in which terminally differentiated cells with specialised functions 




The process where dedifferentiated cells return to their original specialised form. 
 
Chondrogenesis 
The formation of cartilage proceeds in two main stages: condensation and differentiation. During 
condensation, the cell‑cell adhesion molecules N‑cadherin and N‑CAM are key players, while in the 
differentiation stage the cell‑matrix interactions are more important. 
 
Extracellular matrix 
The extracellular matrix of cartilage consists of a network of collagens that provide tensile strength 
and proteoglycans responsible for osmotic swelling and the elastic properties, serving as a scaffold for 
the chondrocytes and as a reservoir for growth factors and cytokines.  
 
Integrins 
Transmembrane glycoproteins built from one α and one β subunit that interact with extracellular 
matrix outside the cell and the cytoskeleton inside the cell. These receptors facilitate both cell‑matrix 
and cell‑cell cross talk. 
 
Monolayer culture 
Cells that are enzymatically relieved from the surrounding matrix and allowed to adhere to and expand 
in plastic flasks or vessels in a single layer fashion, most commonly composed of a single cell type.  
 
Spheroid culture 
Cells are collected in spheroids by gravity (hanging‑drop method) or centrifugation (pellet method), 
and propagated in chondrogenic medium. In the works presented in this thesis, the method is used to 
assess chondrogenic potential of chondrocytes. 
 
Suspension culture 
Cell cultures established by gentle enzymatic digestion of tissue and incubation of cells in ultra‑low 






1.1 Articular cartilage 
Hyaline cartilage is an avascular, aneural and alymphatic tissue covering the ends of long bones 
facilitating a frictionless movement and absorption of forces in the diarthrodial joint. The thickness of 
cartilage is related to the congruency of the joint, ranging from 1.2 mm in the congruent ankle joint to 
2.17 mm in the incongruent knee joint of adults (1), while in adolescents knee joints the thickness 
range up to 4 mm (2). Cartilage consists of only 3‑4 % cells, while the bulk of the tissue is the 
surrounding matrix made up of collagen type II and glycosaminoglycan that provide structural 
architecture and captures water molecules. The tissue is spatially organised in a superficial, middle, 
deep and calcified zone. While most reports have named the chondrocyte as the sole cell type in 
cartilage, newer publications have reported progenitor cells residing in the superficial layer (3). The 
zonal organisation of the matrix facilitates the highly specialised mechanical properties of hyaline 
cartilage. The superficial zone is designed to handle the sheer forces of the moving joint with flattened 
chondrocytes and fibrils arranged parallel to the joint surface. The compressive forces are handled by 
the obliquely organised middle layer and particularly the deep layer where the cells are arranged in 
columns and the fibrils run perpendicular to the joint line (4). The tidemark is the basophilic line on 
histological sections separating the hyaline cartilage from calcified cartilage, while the cement line 
separates the calcified cartilage from the subchondral bone plate (5). The zonal organization is 
reflected in the chondrocytes exhibiting different phenotypes in the superficial, middle, deep and 
calcified zones (6). 
 
Figure 1 Zonal architecture of cartilage (a), micrograph of Safranin O stained sections of cartilage of the 
superficial zone (b), middle zone (c), deep zone (d) and calcified zone (e). The image is reprinted from Grogan et 
al. 2009 (7).  
In addition to the zonal organisation, the cartilage can also by described by pericellular, territorial and 
interterritorial regions. One or a few chondrocytes are organised in chondrons where they are spaced 
by pericellular matrix dominated by proteoglycans, collagen type VI and membrane receptors called 
integrins that anchor the chondrocyte to the surrounding territorial matrix. The interterritorial matrix 




matrix surrounds the chondrocyte by 2 µm, the territorial matrix occupies the area 2‑5 µm from the 
chondrocyte and the interterritorial matrix is spaced more than 5 µm from the chondrocyte (9). The 
matrix captures 65‑80 % water in the tissue, leaving the dry weight of the extracellular matrix at 
around 20‑35 %. The matrix constituents have a long half‑life where collagen type II for instance, has 
a half‑life of >117 years (10). 
 
Figure 2 Cartilage territorial organization. Reprinted by permission from Macmillan Publishers Ltd: Nature 
Reviews Rheumatology (11), copyright 2011 
Due to its shock absorbing and articulating functions, articular cartilage cannot afford blood, lymph or 
nerve supply. The chondrocyte is well adapted to hypoxia and low O₂ tension is necessary for the 
chondrocyte to retain its phenotype and support the matrix homeostasis (12). The avascular and 
alymphatic nature of cartilage leaves nutrients exchange to diffusion from synovial fluid and to a 
lesser degree the subchondral bone. The oxygen tension forms a gradient from around 10 % in the 
superficial zone down to 1 % in the deep zone. The oxygen consumption of the chondrocyte is about 
2‑5 % of that of the liver or kidney cell. Chondrocytes produce energy by glycolysis, and the resulting 
lactic acid molecules are ionised and removed from the cell. The deep zone is thus characterised by 
low O2, low glucose and low pH, and the lactate level in synovial fluid is 5‑8 nM compared to 1 nM 
in serum (13). Importantly, the avascular nature of cartilage implies that the tissue lacks the 
competence to heal once injured or diseased. 
In the ageing cartilage, the tidemark that separates calcified and uncalcified cartilage moves towards 




is replaced by bone. Thus, the thinning of the cartilage is not only a result of continuous wear and tear, 
but also a result of calcified cartilage being replaced by bone (14). 
 
Figure 3 Thinning of cartilage. Safranin O stained sections of human femoral condyles from 40‑year‑old (left), 
76‑year‑old (middle) and 88‑year‑old OA (right) donors. Reproduced from Lotz et al. 2012 (15), with permission 
from Elsevier. 
1.2 Osteoarthritis 
The Osteoarthritis Research Society International have suggested the following definition of 
osteoarthritis in their 2015 review (16):  
“Osteoarthritis is a disorder involving movable joints characterised by cell stress and extracellular 
matrix degradation initiated by micro- and macro-injury that activates maladaptive repair responses 
including pro‑inflammatory pathways of innate immunity. The disease manifests first as a molecular 
derangement (abnormal joint tissue metabolism) followed by anatomic, and/or physiologic 
derangements (characterised by cartilage degradation, bone remodelling, osteophyte formation, joint 
inflammation and loss of normal joint function), that can culminate in illness.” 
 
Figure 4 OARSI definition of osteoarthritis. The molecular disease represent early asymptomatic OA that 
precedes physiological and anatomic aspects by years. This makes it challenging to detect the disease at an 
early stage, but also represents a window of opportunity to discover new early markers. Figure reprinted from 
Mobasheri et a 2017 (17). 
In the clinical setting, the diagnosis of OA is based on the patient’s history of pain and disability, 
supported by radiological evaluation by x‑ray, MRI or ultrasound. The radiological findings on x-ray 
can be graded according to the Kellgren and Lawrence score that levels OA deterioration from none to 
severe (18). The prevalence of this debilitating disease was reported to 12.8 % in Norwegian study of 




their fifties and sixties the prevalence of knee OA alone was 12.2 % (19). Radiological confirmed OA 
of the knee was estimated to 3.8 % on a global scale in data from 2010 including everyone over the 
age of thirty (20). The drawback of resting solely on radiologic assessment is that the association 
between radiological findings and clinical presentation is weak (21). With the rise in life expectancy, 
along with an increase in other risk factors such as obesity, joint trauma and metabolic disorders, OA 
prevalence has been predicted to rise up to 50 % over the next 20 years (22). 
OA has been considered a “wear and tear” initiated degeneration of the cartilage, but the condition 
involves the entire joint including subchondral bone, meniscus, ligaments, tendons, synovium and 
muscles (21,23). The idea of an inflammatory component is not new, it was introduced in Ehrlich’s 
report on hand OA from 1975 (24). With recent advances, it has become clear that molecular 
inflammation is a contributor, and that tissue degeneration and inflammation interact in a vicious 
circle once initiated. Pro‑inflammatory substances such as nitric oxide (NO), prostaglandin E₂ (PGE₂), 
interleukin‑1β (IL‑1β), IL‑6 and IL‑8 are upregulated in OA and induce a molecular inflammation that 
is not necessarily clinically visual, but leads to an interruption of cartilage homeostasis and 
progression of articular degeneration (25,26). Since most cases of OA are idiopathic and symptoms 
present gradually, the inception is very difficult to determine (27). As opposed to rheumatoid arthritis 
where the inflammation is orchestrated by migratory inflammatory cells, the inflammation in OA is 
triggered by resident cells in cartilage or synovium (28). Whether the inflammatory cascades is 
initiated by chondrocytes or synoviocytes, or even subchondral bone, is thus a matter of debate. Early 
signs of degradation can be detected using modern imaging and arthroscopy technologies, but it is 
likely that the cellular and molecular changes in OA start long before damage is clinically detectable. 
OA may have miscellaneous origins and may progress differently in different individuals. During 
recent years, new classifications for OA have been proposed based on different phenotypes. In the 
end, all phenotypes converge in a common pathway leading to painful, stiff and poor-functioning 
joints. 
 
Figure 5 Osteoarthritis phenotypes. Osteoarthritis is a heterogeneous disease originating from different 
phenotypes. Some phenotypes may be more responsive to pharmacological treatment, while other will be less so, 




In the initial stages of OA, proliferative chondrocytes form clusters in order to adjust to the changing 
microenvironments (29). In normal cartilage, aggrecan is found only in an aggregated configuration of 
about 100 aggrecan molecules per hyaluronan molecule. In OA, aggrecan occur in a nonaggregated 
form and the levels decrease, which alters the mechanical compliance of the matrix. Collagen 
production is upregulated, but switches to production of collagen type I instead of collagen type II. 
Collagen type I builds shorter collagen fibrils and this makes the cartilage less able to store elastic 
energy and thus susceptible to fibrillation and fissure formation (30). Progression of OA is 
characterised by elevated levels of IL‑1β and TNF‑α which increase the expression of cartilage 
degrading matrix metalloproteinases (MMPs, i.e. MMP1 and MMP13) and aggrecanases (ADAMTS4, 
ADAMTS5). Chondrogenic growth- and transcription factors including transforming growth factor‑β 
(TGF‑β), sex determining region Y‑box 9 (SOX9), insulin‑like growth factor (IGF) and connective 
tissue growth factor (CTGF) are downregulated, prompting a suppression of anabolic activity. The 
skewed balance between anabolic and catabolic mechanisms in the matrix drastically change the 
mechanical properties. Initially the extracellular matrix softens due to looser collagen networks 
allowing the aggrecan to swell (31). As OA progresses, the level of hydrating aggrecan decrease, 
collagen fibrils stiffen and subsequently more load is transmitted to the underlying subchondral bone. 
These mechanical changes triggers an advancement of the subchondral bone towards the cartilage 
surface contributing to cartilage thinning; but also bone marrow oedema, subchondral cysts and 
periarticular osteophytes. The altered stiffness of the matrix pushes dedifferentiation of the 
chondrocyte towards a fibrochondrocytic phenotype (30). All evidence taken together suggests that 
inflammation could have a pivotal role in OA pathogenesis and that developing therapeutic agents 
targeting inflammation may be a way of preventing or reducing the progression of the disease (32). 
 






1.3  Cartilage injuries 
Healthy cartilage can take loads up to 25 MPa, but exceeding this limit cause chondrocyte death and 
cartilage fissure (34). Three different levels of damage are described with different healing potentials 
accordingly: (1) damage to cells and matrix without visible damage to joint surface, (2) visible 
mechanical disruption limited to cartilage, (3) intra-articular fractures. Partial cartilage injuries heal 
poorly, while intra-articular fracture heal via an initial fibrin clot to a final composition intermediate 
between hyaline and fibrocartilage (34). Traumatic cartilage injuries are usually the consequence of 
major knee traumas like anterior cruciate ligament or multiple ligament injures, but repetitive minor 
trauma could also be the aggressor. Osteochondritis dissecans is a joint disorder that is characterised 
by changes in the subchondral bone and articular cartilage including softening, swelling, early 
separation, partial detachment or complete osteochondral separation with a loose body. Although the 
condition has been known for almost 200 years the aetiology is still elusive. Trauma and repetitive 
micro-trauma has become accepted as a possible cause since the incidence is high among athletes (35). 
Primary osteonecrosis stems from impaired perfusion of the subchondral bone leading to an initial 
collapse of the bone and secondary deterioration of the overlying cartilage, while a secondary form is 
observed after the use of corticosteroids or abuse of alcohol (36). Patients who sustain a severe knee 
injury have about 50 % chance of developing posttraumatic OA, and these patients account for 12 % 
of all OA cases (27). The natural history of cartilage injuries is not completely unravelled and many 
patients achieve favourable long‑term clinical outcomes after localised cartilage injuries left untreated 
(37). The patients that do develop painful and dysfunctional joints after injury represent a treatment 
challenge; the so called: “young patients with old knees” (38).  
 
Figure 7 Endogenous and environmental factors contributing to OA initiation and progression. The combination of 





1.4 Cartilage repair techniques 
A number of clinical strategies to repair cartilage damage have been proposed and tested. Modes 
include pharmacological and surgical techniques (36). The autologous chondrocyte implantation 
(ACI) procedure was first described by Brittberg et al. in 1994 (39), and involves a two‑step 
procedure starting with arthroscopic evaluation of the injured joint and harvest of a cartilage biopsy 
from a healthy, non‑weight bearing area. The biopsy is minced, enzymatically digested and serially 
expanded in monolayer culture vessels until sufficient number of cells are generated for implantation 
via a mini-arthrotomy. At the time of chondrocyte implantation, the defect is stabilised by removing 
any damaged tissue from the defect. A periosteum flap is sutured and glued to the defect and the cell 
suspension is injected under the flap. The method has since evolved by replacing the periosteum with 
a collagen membrane, which has alleviated the problem of hypertrophy of the repair tissue 
encountered in the first generation procedure. The expansion of chondrocytes in monolayer cultures is 
however flawed by the dedifferentiation of chondrocytes into a fibrocartilage phenotype that 
produce collagen type I instead of collagen type II. Implantation of irreversibly dedifferentiated 
chondrocytes may be why some patients have worse outcomes than others (40), and identifying tools 
that enables selection of patients or chondrocytes with properties that favour a good outcome is of 
great interest in order to improve the technique. Implantation of characterised chondrocytes displaying 
a chondrocyte-phenotype was introduced to improve hyaline cartilage formation (41). This procedure 
has evolved into seeding the cells in 3D membrane scaffolds to facilitate the retention of chondrocyte 
phenotype before implantation (matrix assisted chondrocyte implantation, MACI). 
 
Figure 8 Cartilage regeneration techniques. a) Cartilage lesion, b) debridement of lesion, c) microfracture, d) ACI, 
e) MACI. Figure reproduced from Makris et al. 2015 (42). 
Another treatment option not subjected to ex‑vivo expansion of cells is microfracture, a technique 
introduced by Steadman and Rodrigo in 1994 (43) based on the initial report by Pridie in 1959 (44). 
Concerns about the quality and durability of the repair tissue derived from this method has been 
posted (45). Autologous matrix-induced chondrogenesis (AMIC), is a refinement of the microfracture 
technique where a collagen type I/III matrix is added to improve mechanical stability and thus the 
quality of the repair tissue (46). Studies comparing the clinical outcome of AMIC compared to other 




Since the advent of ACI, a plethora of methods to regenerate cartilage has been investigated. Broadly, 
the approaches can be divided into cell‑based methods, scaffold based methods and tissue-engineered 
grafts (47). Cell‑based methods explore the use of chondrocytes, mesenchymal stem cells, embryonic 
stem cells and induced pluripotent stem cells, and rely on replicating the precartilaginous 
mesenchymal condensation. Mesenchymal stem cells can be harvested from bone marrow, synovial 
tissue, the infrapatellar fat pad, subcutaneous fat or muscle, thus eliminating the donor site morbidity 
associated with harvesting cartilage. Cells seeded in protein-, polysaccharide- and synthetic scaffolds 
providing a 3D environment that promotes chondrogenic differentiation have been tested in clinical 
studies (48). The optimal scaffold should have mechanical properties matching the existing cartilage, 
ability to integrate with adjacent cartilage and sufficient durability. Tissue engineering aims to build 
cartilage constructs from combinations of cells and scaffolds or through scaffold‑free approaches. 
Mechanical stimulation, oxygen tension and 3D environment are used to induce chondrocyte 
differentiation and matrix production. In addition, biological factors like TGF‑β and other growth 
factors can be combined with any of the above methods in order to induce chondrogenesis. Yet a 
different approach is the mosaicplasty where cartilage cylinders are harvested from a non‑weight 
bearing part of the joint and transplanted into the injured site, albeit this method is hampered by 
donor‑site morbidity. 
1.5 The chondrocyte 
The chondrocyte communicates with the surrounding matrix via membrane receptors and organelles 
like cilia and caveola (49). The normal chondrocyte has a low turnover, replacing resilient cartilage 
matrix proteins. Once the cartilage is injured or OA is induced the chondrocyte metabolism increase 
and the balance between synthesis and degradation of matrix protein is disrupted. Degradation 
products interact with cell‑surface receptors and induce an increased production of matrix-degrading 
proteinases (50). The collagen expression pattern shifts toward type III, VI, X and a chondroprogenitor 
splice variant of collagen type II (type IIA) (51). This central role in OA pathogenesis has made the 
chondrocyte the target of OA therapy (50), aiming to inhibit the synthesis and activity of cytokines 
and proteinases or enhance the repair capacity. 
1.5.1 Lipid mediators/arachidonic acid 
Mounting evidence point to proinflammatory cytokines IL‑1β and TNF‑α as key players in cartilage 
degradation. IL‑1β and TNF‑α stimulate the synthesis of proinflammatory prostaglandins through the 
induction of the catalyst enzyme cyclooxygenase (52). Prostaglandin E₂ has been reported to have a 
dual effect in cartilage, both enhancing collagen type II and proteoglycan synthesis by counteracting 
IL‑1, and stimulating the production of degrading MMPs (53).  
When a cell suffers injury or other stimuli, phospholipases in the cell membrane are de‑esterified into 
arachidonic acid by phospholipase A2. The enzymes cyclooxygenase (COX) ‑1 and ‑2 convert the 
arachidonic acid to prostaglandin E₂ (PGE₂) while 5‑lipoxygenase (5‑LOX) along with 5‑lipoxygenase 
activating protein (FLAP) convert arachidonic acid to leukotriene A₄ (LTA₄). Leukotriene A₄ 
hydrolase rapidly convert LTA₄ to LTB₄. The level of eicosanoids like PGE₂ and LTB₄ in synovial 
fluid is elevated in inflammatory joint disease like osteoarthritis and rheumatoid arthritis. The source 
is primarily the synovial membrane (54,55), but the chondrocyte can synthesise PGE₂ under IL‑1 and 
TNF‑α stimulation (50). Non-steroidal anti‑inflammatory drugs (NSAIDs) are widely used in the 




fluid. Studies have indicated that inhibiting the COX-pathway will shunt the conversion over to the 
5‑LOX arm resulting in higher levels of LTB₄ (53,56,57).  
 
Figure 9 Arachidonic acid (AA) biosynthesis of prostaglandins (PG) and leukotrienes (LT). Black boxes indicate 
receptors. Figure reproduced from Charbeneau et al. 2005 (58). 
The LTB₄ receptors were discovered by Yokomizo et al. who in 1997 described a G‑coupled receptor 
that mediates chemotaxis (59). The high‑affinity receptor was called BLT1 and was reported to be 
found primarily in leukocytes. In 2000 a low‑affinity receptor was discovered and designated BLT2 
(60). This receptor is ubiquitously expressed and also recognises other lipoxygenase metabolites (61). 
A third group of receptors has been identified in the peroxisome proliferator-activated receptors 
(PPARs) that reside in the nucleus and govern lipid homeostasis and inflammatory responses (62,63). 
Initially, the role of the LTB₄ - BLT interaction was identified as a host defence mechanisms against 
infection, acting specifically in the recruitment of neutrophils. In time, it became evident that the 
system was also active in inflammatory joint diseases where LTB₄ upregulates the synthesis of IL‑1β, 
TNF‑α and MMPs by cells residing in the synovial membrane. Human articular chondrocytes express 
5‑lipoxygenase, FLAP and LTA₄ hydrolase, and are thus capable of converting arachidonic acid into 
leukotrienes (56,64). When chondrocytes are stimulated with growth factors such as TGF‑β and 
1α,25‑dihydroxyvitamin D₃, the synthesis of 5‑lipoxygenase, FLAP and LTB₄ increase. Naproxen, an 
NSAID, is reported to induce LTB₄ production that triggers an increased production of MMP1, 
implying the presence of a BLT1 receptor in chondrocytes (56). A potential role of LTB₄ in OA was 
suggested through studies on chondrocytes where blocking of the 5‑lipoxygenase/FLAP pathway 
suppressed the levels of inflammatory mediators (65). Mice whose BLT1 gene was knocked out were 
protected from the development of collagen induced rheumatoid arthritis (66). The role of LTB₄ in 
rheumatoid arthritis was further investigated and the effect was primarily believed to be conveyed 
through BLT1 and BLT2 receptors on leukocytes, macrophages, dendritic cells and mast cells in the 





1.5.2 Vitamin D 
Vitamin D is a secosteriod that occurs naturally as vitamin D₃ in mammals and as vitamin D₂ in fungi. 
The term vitamin is actually a misnomer as the main source is via endogenous production in 
sun-exposed skin where 7‑dehydrocholesterol is transformed to previtamin D₃ and immediately to 
vitamin D₃ (cholecalciferol) via UV light and heat induction. Vitamin D is transported to the liver 
where it is hydroxylased to 25‑hydroxyvitamin D₃, 25(OH)D₃, and this stable metabolite is measured 
in the serum to determine the vitamin D status. From the liver the 25(OH)D₃ is transported to the 
kidney where it enters cells in the proximal tubule that exhibit mitochondrial P450 1α‑hydroxylase 
activity that catalyse the formation of the active hormone form; 1α,25‑dihydroxyvitamin D₃ 
(1α,25(OH)₂D₃) (69). In addition to the endogenous production, vitamin D can also be obtained 
through fatty fish and fortified food items. Vitamin D tightly regulates the calcium and phosphorous 
homeostasis, securing the calcium level in plasma and bone mineralisation (70). It acts via the vitamin 
D receptor (VDR) that complexes with retinoic acid X receptor (RXR) in the nucleus (71). In the 
small intestine the 1α,25(OH)₂D₃ regulate calcium and phosphorus absorption, while in a state of 
dietary calcium deficiency the 1α,25(OH)₂D₃ will act on the bone to release precious calcium and 
phosphorous stores into circulation to maintain adequate physiological levels. The binding of 
1α,25(OH)₂D₃ to VDR also regulates cellular differentiation and proliferation (72). 
 
Figure 10 The biosynthesis of vitamin D and major effects on organs. Pi: inorganic phosphate, Ca: calcium, PTH: 
parathyroid hormone. The figure is reproduced from Mabey et al. 2015 (73). 
Clinical studies have indicated that inflammatory joint diseases, like osteoarthritis and rheumatoid 
arthritis, are more prevalent in people deficient of vitamin D (73). At the same time, the level of 
1α,25(OH)₂D₃ in the synovial fluid has been shown to be elevated in patients suffering from 
inflammatory joint conditions (74). Clinical studies have tried to establish whether vitamin D 
supplements reverse this effect or perhaps has a protective effect in those with symptoms of 
osteoarthritis. The results are so far controversial, ranging from no effects to improvement of pain and 
activity scores (75), and even structural effects (76). Recent studies have failed to detect any impact of 
vitamin D on radiographic osteoarthritis or joint space narrowing (77). 
The role of vitamin D in inflammatory joint disease is likely played by local (extrarenal) production of 




1α,25(OH)₂D₃ (78,79). Joint tissues and cells including osteoblasts, osteoclasts, synovial fibroblasts 
and macrophages exhibit 1α‑hydroxylase activity (80) and the vitamin D receptor has been detected in 
cartilage and synovial tissues, most notably during inflammatory conditions (81,82). In the kidney the 
1α‑hydroxylase is regulated by its end product and activated by calcitonin and parathyroid hormone 
(72), while in joint tissues the 1α‑hydroxylase is regulated by less elucidated mechanisms (83,84). The 
single gene encoding both renal and extrarenal 1α‑hydroxylase, is CYP27B1 (69). When expressed in 
the kidney, the gene is upregulated by parathyroid hormone and downregulated by fibroblast growth 
factor 23 (FGF23) (85). Regulation of CYP27B1 and VDR expression has been investigated in 
primary human osteoblasts, where calcium had a positive effect on CYP27B1 gene expression, while 
VDR was dose dependently upregulated by 25(OH)D₃ and 1α,25(OH)₂D₃ (84,86).  
 
Figure 11 Endocrine vs autocrine/paracrine effects of vitamin D. Vector drawings are from Colourbox.com. 
1α‑hydroxylase also acts on the fungi-derived vitamin D₂ (ergocalciferol), which is used as a vitamin 
D supplement. It has been questioned whether vitamin D₃ and vitamin D2 are equivalent as vitamin D 
supplements, as some argue that the long term effect of vitamin D₃ supplementation is more efficient 
than that of vitamin D2 (87). 
1.5.3 Cell‑surface receptors 
The chondrocyte express a multitude of cell-surface receptors involved in communication between the 
cell and its surrounding matrix. A number of such receptors have been suggested as potential 
biomarkers to predict chondrogenesis in vitro or improved clinical outcomes after cell-based therapies. 
Integrins 
Integrins are heterodimeric cell‑surface receptors composed of one α and one β subunit. These 
receptors are involved in cell‑cell and cell‑matrix interactions, and mediate the attachment of the cell 
to extracellular matrix and signal transduction from extracellular matrix to the cell. In mammals, 18 α 
and 8 β subunits are known, while chondrocytes express a subset of 8 α and 3 β subunits (88,89). 
Integrins functionally interact with extracellular matrix and the cytoskeleton, as well as growth factors 
and their receptors (90). Typical ligands are collagen, laminin, vitronectin, osteopontin and fibronectin 
(91). Through their short cytoplasmic tail, integrins signal downstream by recruiting an array of signal 






Figure 12 Integrins. Figure reproduced from Moura‑Neto et al. 2014 (93). 
Integrins have no intrinsic enzymatic activity but become activated after binding of the extracellular 
ligand and undergo conformational changes that propagate across the membrane to activate 
cytoplasmic kinase- and cytoskeleton signalling cascades that control cell attachment, response to 
mechanical load, responsiveness to growth factors, differentiation and survival (90,94). Normal 
chondrocytes express integrins α1β1, α2β1, α5β1, α6β1, α10β1, αVβ3 and αVβ5 while OA 
chondrocytes express high levels of β1 and all of the α chains (92,94). 
The central role of integrins in communication between the chondrocyte and the matrix has elicited an 
interest in these receptors as potential key players in chondrogenesis. In cell culture studies the 
expression of integrin β1 and integrin α3 has been linked to increased chondrogenic potential (95–97). 
Other cell‑adhesion molecules and cell‑contact receptors 
Other relevant cell adhesion molecules more involved in cell‑cell interactions comprise N‑cadherin 
(CDH2) and neural cell adhesion molecule (N‑CAM), which play vital roles during the initial cell 
condensation stage of chondrogenesis, where cell‑cell communication is crucial. N‑cadherin is a 
calcium-dependent glycoprotein in the cadherin superfamily that recognise cadherin molecules on 
other cells, thus facilitating cell condensation. Downregulation of N‑cadherin is necessary to switch 
from condensation to differentiation. The calcium independent glycoprotein N‑CAM is a member of 
the immunoglobulin superfamily. N‑CAM recognise other cell adhesion molecules and regulates the 
condensation process. Both molecules are lost upon differentiation and continued expression is linked 
to inhibition of chondrogenesis (9). 
The surface molecule CD44 is the main receptor of hyaluronic acid and crucial for the maintenance of 




chondrocyte surface (99), CD44 contributes to the structural organisation of the pericellular matrix 
(100) as illustrated in Figure 2. During inflammatory conditions, the intercellular adhesion molecule 1 
(ICAM‑1, also termed CD54) is induced, and functions as a hyaluronic acid receptor along with CD44 
(101). In a study comparing chondrogenic potential of stem cells from various sources, including bone 
marrow and subcutaneous fat, the expression of ICAM-1 was a predictor of poor chondrogenic 
potential (102), while in another study the increased expression of ICAM-1 was linked to a favourable 
chondrogenic potential of umbilical cord blood stem cells compared to bone marrow stem cells (103). 
Higher expression of tetraspanin (CD151) and activated leukocyte cell adhesion molecule (ALCAM, 
CD166) by chondrocytes have been associated with increased matrix production during 3D culture 
(97), while sorting out CD146 (melanoma cell adhesion molecule, MCAM) positive chondrocytes was 
linked to improved chondrogenesis (104). Specific selection of cells with high expression of CD271 
(low‑affinity nerve growth factor receptor) and low expression of CD106 (vascular cell adhesion 
molecule, VCAM‑1) has also been associated with improved quality spheroids (105). 
TGF‑β receptors superfamily 
In chondrocytes and MSCs the TGF‑βs are major regulators of chondrocyte lineage selection and 
cartilage matrix synthesis while actively blocking terminal differentiation and hypertrophy (14,90). 
Mechanical loading of cartilage triggers the release of TGF‑β. In the absence of loading, this 
mechanism can be mimicked by the addition of exogenous TGF‑β. BMP‑2, ‑4 and ‑6 have the ability 
to enhance the chondrogenic effect of TGF‑β, where BMP‑2 has been shown to be most efficient at 
inducing chondrogenesis in the combination with TGF‑β3 (106,107). 
The transforming growth factor‑β (TGF‑β) and bone morphogenetic protein (BMP) both belong to the 
TGF‑β superfamily of polypeptide signals that the human organism rely on to control a range of cell 
functions including differentiation, tissue repair and inflammation. The TGF‑βs and BMPs bind a 
receptor complex made up of one type I receptor subunit (activing receptor‑like kinase, ALK 1‑7) and 
one type II receptor subunit. More specifically the TGF‑βs utilise ALK1 or ALK5 (transforming 
growth factor‑β receptor I, TGFBRI) as the type I receptor and TGFBRII as the type II receptor, while 
BMPs signals through ALK1, ALK2, ALK3 (BMPR1A) or ALK6 (BMPR1B) as the type I receptor 
and BMPRII as the type II receptor. The membrane‑anchored type III receptor, TGFBRIII or 
betaglycan, captures TGF‑β for presentation for the signalling receptors I and II (108,109). 
The type I receptor involved in the signalling governs the downstream activation cascade. When the 
signals are transmitted via ALK1, ALK2, ALK3 or ALK 6, the SMAD1/5/8 complex is 





Figure 13 TGF‑β signalling. Reprinted by permission from Macmillan Publishers Ltd: Nat Rev Rheumatol. (109), 
copyright (2017). 
This means that the TGF‑βs can activate both the SMAD1/5/8 (via ALK1) and the SMAD2/3 pathway 
(via ALK5), while BMPS activate SMAD1/5/8 (14,110). The ALK5 pathway is the main pathway in 
healthy and young cartilage allowing TGF‑β to act as a chondroprotector, while in ageing cartilage 





2 Aims of the thesis 
The overall aim of the work presented in this thesis was to investigate the biology of certain 
inflammatory and other cell signalling receptors on human articular chondrocytes and to ascertain 
whether such receptors play any relevant role in chondrogenesis, cartilage homeostasis and/or 
cartilage repair. 
The specific subaims were: 
1) To explore the expression of functional leukotriene B₄ receptors in human articular chondrocytes 
and to elucidate if receptor engagement had effects on chondrogenesis and other major 
chondrocyte functions. 
2) To determine whether human articular chondrocytes express the vitamin D receptor and the 
vitamin D activating enzyme 1α‑hydroxylase, and to elucidate if vitamin D exerts relevant effects 
on chondrocyte functions and cartilage homeostasis. 
3) To search for putative biomarkers associated with superior chondrogenic potential for patient 





3 Methodological considerations 
This chapter aims to discuss important aspects related to the materials and methods used in this thesis 
work, as well as to comment on some strengths and limitations associated to the chosen methodology. 
3.1 Biological material 
In Papers I and II cartilage tissue harvested from patients undergoing total knee replacement, was used 
for experimentation. Patients were invited to donate tissue only if the medical history gave no reason 
to suspect rheumatoid origin of the arthritis. The cartilage was harvested from a healthy looking area 
of the joint, usually the lateral femoral condyle. The tissue was still regarded as OA tissue since 
degeneration severe enough to warrant a joint replacement is generally considered a disease of the 
whole joint, including the healthy looking areas. As indicated in Figure 3 of the introduction, the 
composition of ageing and OA cartilage is different from that of normal young cartilage. Although the 
incidence of knee OA is higher in women, the cartilage composition appears to be comparable 
between the genders (111). The results from these studies are thus limited to the context of OA 
cartilage and any attempt of extrapolating to normal cartilage conditions must be performed with 
caution.  
In paper III, and some experiments in paper I, surplus chondrocytes from ACI procedures were used 
for experiments. These cells are generally considered healthier than the cells generated from knee 
replacement surgery since the indication for ACI is a localised cartilage defect and not a whole-joint 
disease. Overall, the surplus cells proliferated more rapidly than the cells harvested from OA knees as 
an indicator of younger and healthier cells (112). 
The research project was evaluated by the regional ethics comity (REC). Since we have several 
ongoing projects in our group, we hold a permission to include chondrocytes from knee replacement 
procedures and ACI procedures in a biobank, given the written approval by the patient. A REC 
approval was obtained for the use of the cells for the research questions outlined in the different 
papers, serving as an external evaluation of the research question and ethical considerations. The REC 
evaluation ensures that the obtained samples are used for research that is meaningful for the public and 
the patient, and safe for the participating patients. 
3.2 Cell culture systems 
Freshly isolated chondrocytes (directly harvested from enzymatic digestion of the tissue) and 
short‑term suspension cultures hold a differentiated stage, demonstrated by gene expression profiles 
comparable to that of native chondrocytes (113). However, cartilage cells dedifferentiate after 
successive cell divisions in adherent cultures, losing their original traits and switching to a more 
fibroblastic phenotype characterised by increased production of collagen type I and versican, and 
decreased amount of collagen type II and aggrecan (114). Consequently, findings using monolayer cell 
cultures should be cautiously interpreted, and cannot be directly extrapolated to native cartilage 
conditions. To circumvent the problem of cell dedifferentiation in vitro, we introduced a suspension 
culture model in Paper II enabling experimentation of cells holding a native phenotype (115). 
Cells were isolated from cartilage by mincing the freshly harvested cartilage into sub ~1mm³ pieces 
under sterile conditions followed by enzymatic digestion in collagenase XI at a final concentration of 




from the collagenase and undigested pieces by a 70 µm cell strainer and subsequent centrifugation 
before they were resuspended in fresh medium. The freshly isolated cells were mixed with Trypan 
blue solution, and the number of live and dead cells was assessed using a haemocytometer. Initial 
experiments using overnight digestion resulted in up to 50 % dead cells. The experimental conditions 
were optimised and at 4‑6 hours digestion, the amount of dead cells was negligible. 
Henceforth the cells were used in static suspension cultures or expanded in monolayer cultures. In 
static suspension cultures, 4 × 10⁵ freshly isolated cells were propagated in 800 µL medium in 
ultra-low attachment 24-well plates. After 24 hours of equilibration, the cells were stimulated and 
harvested. This approach allowed experiments on differentiated chondrocytes. However, a limitation 
of the static suspension culture is the relative low amount of cells harvested from each cartilage 
specimen. In order to draw samples for both protein- and gene assays, a minimum of 4 × 10⁵ cells per 
experimental condition was necessary. Generally, this required cartilage samples exceeding 1‑2 grams. 
Another drawback is the relative high amount of cartilage-derived extracellular matrix proteins in the 
cultures, which could represent a problem when analysing results of Western blots. 
The 3D culturing method supports redifferentiation of chondrocytes back to a chondrocyte-like 
phenotype (9). Our lab employ two different methods to prepare 3D cultures: the pellet culture system 
and the hanging drop system (116). In the hanging drop method, drops of 2 × 10⁴ chondrocytes are 
applied to the lid of a 24‑well plate, next the lid is inverted so that the drops are suspended from the lid 
driving the chondrocytes to converge in the tip of the drop by gravitational forces. To avoid 
dehydration the hanging drop pellets are suspended over wells filled with medium. The pellet method 
applies conical‑bottom 96‑well plates that are coated with poly‑HEMA to prevent cell adherence. 
After dispensing 5 × 10⁴ chondrocytes/150 µL medium/well, the plate is centrifuged at 1100 × g for 10 
minutes to allow the formation of pellets. Alternatively, an ultra‑low attachment 96‑well round‑bottom 
plates is applied, followed by 5 min centrifugation at 500 × g. In either hanging drop or pellet 
approach, early formed spheroids are transferred to low attachment 24‑well plates in chondrogenic 
medium after two days in order to secure sufficient access to nutrients. For both methods the spheroids 
are incubated in low (2.5 %) O₂ conditions further promoting chondrogenic differentiation (117).  
Previous studies have shown that if the 3D differentiation is performed during the early expansion 
phase (within 10 days of initial plating), no growth factors are necessary to generate cartilage-like 
micro-tissues. In our setup we generally needed to expand the chondrocytes for 21 days or more to 
obtain sufficient amount of chondrocytes for the planned assays, and in this setting growth factors 
were necessary to induce chondrogenesis (118). This is evident in paper I where ACI surplus cells 
were used for spheroid formation in the absence of dexamethasone and TGF‑β. The omission of 
growth factors was based on the aim to find effects of LTB₄ alone, but the result was that the spheroids 
formed very little matrix in the absence of growth factors. In Paper II, the spheroids were prepared 
from OA chondrocytes and propagated in serum‑free medium containing TGF‑β3, BMP2 and 
dexamethasone. In addition 25(OH)D₃ or 1α,25(OH)₂D₃ was added to evaluate effect on 
chondrogenesis. The untreated spheroids show some ability to produce matrix, but far less than the 
spheroids prepared from ACI surplus chondrocytes in Paper III. These findings reflect previous 
reports stating that OA chondrocytes have lower capability of recovering normal tissue phenotype 






In Papers I and II, immunohistochemistry was applied to evaluate the expression and distribution of 
proteins of interest in cartilage and spheroid sections. Briefly, the method includes formalin fixation of 
the tissue, sectioning and mounting onto slides, blocking of background signalling, peroxidase 
quenching, incubation with a specific primary antibody, incubation with horseradish peroxidase (HRP) 
polymer conjugated secondary antibody and finally development by DAB chromogen. For the BLT1 
and BLT2 receptors investigated in Paper I, the staining was apparent by this protocol alone. 
However, this was not the case for the vitamin D receptor interrogated in Paper II. The formalin 
fixation of the tissue sections can induce modification of the antigens and loss of the ability of the 
antibody to react with the antigen. The recommended method to restore the antigen is by heat‑induced 
antigen retrieval (120). Unfortunately, due to the nature of the cartilage tissue, the heat makes the 
sections detach from the glass. We tested an alternative approach using antigen retrieval at lower 
temperature. When the temperature is decreased the time must be increased to obtain sufficient antigen 
retrieval (121) and the sections were incubated overnight in 60° C retrieval buffer (122). Using this 
more gentle protocol, we still experienced detachment of the sections. We tested both Tris‑EDTA (pH 
9.0) and citrate (pH 6.0) retrieval buffers with similar outcomes, that is; no staining of VDR, while 
1α-hydroxylase was apparent in the superficial layers of OA cartilage sections. The positive control 
tissue (intestinal mucosa) was stained by both VDR and 1α-hydroxylase. We continued 
troubleshooting the VDR staining by testing an antigen retrieval protocol suggested by Tetlow et al., 
where sections were incubated in  2 M HCl at 37° C for 30 minutes (123), but in our hands this did not 
result in staining of the VDR. Lastly we attempted antigen retrieval by enzyme digestion using 
hyaluronidase and pronase as previously described (124), but still we failed to obtain any staining of 
the VDR in OA cartilage and spheroids. The VDR antibody was selected based on the comprehensive 
paper by Wang et al. (125), where the several VDR antibodies were compared in terms of sensitivity 
and specificity. The rigorous validation described in this paper is not available for all antibodies, and 
the experimental setup can be extensive since particularly a true negative control sample, usually from 
knockdown animals, can be challenging to obtain. An alternative approach of validation is to 
immunoblot for bands of the correct molecular weight (126), and this method was applied to the 
antibodies used in Paper II. True positive controls are more easily obtained, exemplified by the 
intestinal mucosa used in Paper II where the expression of both 1α‑hydroxylase and VDR is well 
established. Since the sections of intestinal mucosa were stained through all experimental conditions, 
while the cartilage sections remained unstained, we concluded that the VDR is either absent or 
expressed below the detection threshold of the assay. In all experiments, sections devoid of the 
primary antibody were used as controls of unspecific staining of the secondary antibody.  
3.3.2 Immunocytochemistry 
Immunolabelling by specific antibodies in cultured cells was used in Papers I and II. This method 
enables visualisation of the protein within the cell and as demonstrated in Paper II, the subcellular 
distribution between cytoplasm and nucleus can be evaluated. Cells were expanded on glass slides 
until confluent, fixed and permeabilised by brief incubation in ice‑cold methanol followed by blocking 
of background signals using a 2 % human serum albumin solution. Next, the slides were successively 
incubated with primary antibody and a fluorophore-conjugated secondary antibody followed by image 




equivalent to the outline in section 3.3.1, and the immunoblotting serving as validation for 
immunohistochemistry is thus valid for the immunocytochemistry. Sections lacking of the primary 
antibody were used as negative controls of the secondary antibody. 
The VDR resides in the nucleus in the absence of 1α,25(OH)₂D₃, but to a greater extent in the presence 
of the ligand (127,128). In previous studies this has been demonstrated by Western blot of nuclear vs. 
cytoplasmic fractions of cells (129), but the effect has also been visualised by immunocytochemistry 
in human skin fibroblasts and rat kidney cells (125,130). In order to examine the activity of the VDR 
in chondrocytes we expanded chondrocytes on glass slides before treatment with 1α,25(OH)₂D₃ 
(10⁻⁷ M) for 2 hours before permeabilisation and fixation of the chondrocytes. This assay successfully 
demonstrated the nuclear translocation of the vitamin D receptor.  
3.3.3 Western blot 
Western blot (immunoblotting) was used to evaluate receptor engagement in Paper I by probing for 
phosphorylated protein kinases downstream of the receptor. In Paper II, immunoblotting was used to 
validate that the antibodies used for immunohistochemistry produced bands of the correct molecular 
weight, and for semi-quantitatively assessment of receptor and enzyme regulation. The protocol was 
based on the principles thoroughly outlined by Bass et al. (131). Protein samples were prepared using 
the RIPA (Paper I) or NP‑40 (Paper II) lysis buffer to obtain whole cell extracts. A ratio of 1 mL lysis 
buffer per 0.5 ‑ 1 × 10⁷ cells proved vital to obtain sufficient protein concentrations. As we were 
probing for cell-associated proteins, it was necessary to remove the extracellular matrix prior to cell 
lysis. For native cartilage, this was done by enzymatic digestion of the tissue and subsequent harvest 
by centrifugation. However, we experienced that the levels of extracellular matrix proteins were 
overriding in samples even after suspension subcultures. This can be observed in Figures 1 and 2 in 
paper II where the loading control β‑actin (a cell-associated protein) is substantially lower expressed 
in suspension culture samples compared to monolayer samples, despite that the amount of input 
protein being compensatory increased in the former. This issue has previously been described in RNA 
extraction protocols (132). Others have noted that protein input must be increased in order to detect 
VDR in tissue compared to cells, and that a hyperosmolar lysis buffer facilitating release of DNA-
bound protein may be important (133). The suspension cultures in Paper II were homogenised by 
centrifuging samples through a QIAshredder column, but this did not reduce the difference in β‑actin 
expression. The difference in expression of the loading control between the different culture 
conditions implies that a direct comparison of these samples is inadequate. An alternative 
normalisation method, that may have produced more consistent results in our setting, is the use of 
Coomassie staining (134). A protease inhibitor was used in all conditions, and when probing for 
phosphoproteins (Paper I) a phosphatase inhibitor was included as well. Lysates from osteoblasts were 
used as positive controls of antibody specificity in Paper II. 
Equal amounts of protein from each sample type were separated by gel electrophoresis and the 
proteins blotted onto PVDF membranes. The PVDF membrane has high affinity for proteins, 
including the antibody-proteins. Thus, after blotting, the remaining surface was blocked using milk 
proteins to prevent nonspecific binding of antibodies during subsequent steps. Finally, membranes 
were incubated with primary and secondary antibody followed by chemiluminescence detection using 
a charge-coupled device (CCD) camera. During initial runs of the protocol for Paper II, some 




sample. This feature disappeared upon the use of a fresh batch of protease inhibitor, producing the 
images presented in Paper II. Of note, many proteins exist as isoforms and depending on the primary 
antibody it may or may not be specific for one or more of the isoforms (135). In the case of the latter, 
multiple bands are expected as specified by the supplier or in the literature. 
3.4 Polymerase chain reaction 
The polymerase chain reaction (PCR) exploit the DNA polymerase enzyme that makes copies of 
DNA. By repeating the copy process multiple times, low amounts of DNA or cDNA are amplified to 
levels that can be detected using gel electrophoresis (RT‑qPCR) or fluorescence based detection 
methods (qPCR).  
3.4.1 RNA extraction 
Cellular processes like growth, differentiation and survival can be assessed by measuring the amount 
of messenger RNA in a sample (136). Attempts were made to extract total RNA from cartilage and 
spheroids by crushing the tissues in a mortar under liquid nitrogen, followed by extraction using 
phenol-based lysis buffers. This method was flawed by low reproducibility, low RNA yield and 
phenol contamination as judged by Nano‑Drop spectrophotometry evaluation and qPCR validation 
experiments. An optimised protocol including enzymatic digestion of cartilage, harvest by 
centrifugation and immediate disruption and homogenisation in a phenol free lysis buffer, resulted in 
increased RNA yield increased and low contamination (113). Freshly isolated chondrocytes or intact 
spheroids were processed by mixing the sample and lysis buffer in a 2 mL Eppendorf tubes containing 
a 5 mm stainless steel ball, and subsequent disruption of samples in a TissueLyser bead mill for 2.5 
min at 25 Hz. To homogenise and remove insolubles the samples were passed through QIAshredder 
columns (137). In order to obtain sufficient RNA concentrations, MinElute columns were used for 
subsequent purification of freshly isolated chondrocytes, suspension cultures and spheroids. Extraction 
of RNA from chondrocytes expanded in monolayer cultures is straightforward as there is less 
interference from extracellular matrix (132), the cells can be lysed directly in the culture vessel and 
RNA extracted without further disruption or homogenisation steps to yield high concentrations of 
clean RNA. On-column DNase digestion was performed on all samples to eliminate contaminating 
DNA. 
3.4.2 Reverse transcription to cDNA 
The DNA polymerase acts on double stranded structures and since RNA is single stranded the 
reverse transcriptase enzyme is used to create double stranded cDNA. The reverse transcription (RT) 
process should reflect the amount of RNA input, but the presence of inhibitors can influence the 
efficiency of the reverse transcriptase. Validation of the RT was performed using a dynamic range test 
where RNA was diluted in a five step 1:3 dilution series. Each dilution was transcribed to cDNA and 
amplified by qPCR using a probe with high gene expression level (the reference gene) and a probe 
with low gene expression level (138). The results indicated that the undiluted samples were not 
amplifying at a linear range and the RNA was diluted 1:3 for all subsequent RTs. 
3.4.3 Reverse Transcriptase-PCR 
In reverse transcriptase PCR (RT‑PCR), the cDNA is amplified in the presence of oligonucleotides 
(primers) designed to specifically bind the gene of interest (GOI). The primer serves as a starting point 




end-product is separated by gel electrophoresis and if the primers have been correctly designed, a band 
matching the size of the expected product can be visualised. A reference gene is amplified to control 
loading and purity, as it will produce an extra band in the case of contaminating DNA. The 
end-product corresponds to the plateau phase of the reaction where the substrates are limited or 
exhausted. For various reasons this plateau phase can differ between identical samples and this limits 
the use of RT‑PCR for quantification purposes. It is however useful for determining the presence of 
transcribed genes as we did in Papers I and II (139). 
 
Figure 14 End stage PCR. Illustration of how identical samples can have variable plateau phases. Figure adapted 
from Larionov et al. 2005 (140). 
The primers used in Paper I had been validated in previous publications (141), while for Paper II it 
was necessary to design primers that would identify all homologues of the vitamin D receptor. 
Messenger RNA sequences that were common in all homologues were identified using BLAST (142) 
and tested in the Primer3Plus online software (143). Two different primer pairs for VDR and 
1α‑hydroxylase were tested and the pairs producing the clearest band of the correct size were used in 
the final setup. 
3.4.4 Quantitative real-time qPCR  
Quantitative real-time qPCR (qPCR) depends on the same basic ingredients as the RT‑PCR reaction: 
DNA polymerase, primers and a DNA or cDNA template. In addition, the qPCR reaction incorporates 
a dye that emits fluorescence proportional to the amplification. The fluorescence is detected by the 
qPCR platform and the amplification reaction can thus be followed in real-time. The qPCR reactions 
in this study are based on hydrolysis probes. The hydrolysis probe is an oligonucleotide designed to 
bind the template downstream of one of the primers and is equipped with a fluorescent dye and a 
quencher molecule. The quencher molecule prevents the dye from emitting fluorescence as long as 
they are proximate. During amplification, the polymerase cleave the probe, separating the quencher 






Figure 15 Hydrolysis (TaqMan) probe. Illustration of how the quencher is release during amplification, thus 
allowing the reporter to emit fluorescent light that is captured by the qPCR platform. Figure adapted from 
cogentech.it (144). 
As long as templates (cDNA) and reagents are unlimited, the templates are doubled for each cycle and 
fluorescence thus increase exponentially. When reagents are restricted, the fluorescence follow a 
linear curve and once depleted the reaction enters the plateau phase. 
 
Figure 16 qPCR phases. The figure is reproduced from VanGuilder et al. 2008 (139).  
The hydrolysis probes used in this study are pre-optimised from the vendor and further validation of 
efficiency is reported to be redundant (145), particularly because the validation process itself has some 
pitfalls. Nevertheless, a five step 1:10 dilution series of cDNA from representative samples was 
prepared and each dilution was subjected to qPCR using probes for high (reference gene) and low 
(COL2A1) expressing genes. Excluding the undiluted sample resulted in dilution curves of efficiency 
within the recommended 90 to 110 %. 
Since RNA was extracted from various matrices using slightly different methods it was important to 
identify one or more references genes that were expressed uniformly across the samples (146). 
Validation of the optimal reference gene was performed by using samples from all interrogated 
matrices (freshly isolated chondrocytes, suspension culture chondrocytes, monolayer chondrocytes 




were analysed using the NormFinder and geNorm tools. GAPDH proved to be a stable reference gene 
in studies of monolayer samples, while in studies including cartilage, suspension culture and spheroid 
samples the RPL13A proved to be more stably expressed. Combining two or more reference genes did 
not increase the stability. 
Plates were loaded using the sample maximization method (147), eliminating the need for interplate 
calibrator samples. The Cq values of the gene of interest were normalised by subtracting the Cq value 
of the reference gene (ΔCq = Cqreference – CqGOI). This resulted in ΔCq values that reflect the regulation, 
i.e. higher values mean higher expression and vice versa. The ΔCq values were used for statistical 
testing and were plotted directly using bee swarm plots. Significant up- or downregulation of genes 
was evaluating using t‑tests in setups of few samples and genes (Paper I). For larger assays (Paper II 
and III), an ANOVA was applied, followed by Dunnett’s post hoc test where multiple experimental 
conditions were compared to one control condition (148). 
It is common to present the data as fold change of expression compared to a control sample, the fold 
change can be calculated using the 2ΔΔCq formula where ΔΔCq = mean(ΔCq treated) – mean(ΔCq 
control). The drawback of representing fold change is that any upregulation will be visualised nicely 
taking a value of 1 or more, while downregulation will have a value restricted between 1 and 0. If the 
axis representing the fold change is set to log scale, the up- and downregulation will be given equal 
weight, this option was used in Paper I. Another option is to log the fold-change; this will also give 
equal weight to the up- and downregulation. However, if a log base 2 is used for the log 
transformation, the result is the ΔCq value. Using fold change and log base 2 is thus mathematically 
redundant. Displaying the ΔCq or ΔΔCq values directly will correctly reflect the regulation and this 
option was used in Paper II and Paper III. To ease the interpretation of the results the results in paper 
III were shifted along the scale so that the control sample centers on zero for each gene. Relative 
quantification justifies the comparison of different samples analysed with the same probes, but does 
not allow for comparison between different probes (149). 
In paper II, we compared samples from different matrices from the same donors (treated and untreated 
suspension culture chondrocytes and monolayer chondrocytes). Donor to donor variation exceeding 
the difference in gene expression is a common challenge, which we encountered in Paper II. A 
solution was suggested by Willems et al. (150) who used mean centring and autoscaling to minimise 
the effect of donor-to-donor variation and focus on the difference in gene expression. The authors 
propose to apply the autoscaling and mean centring on log fold-change values, but this is also 
mathematically redundant and the same result is easily achieved by using ΔCq values directly as 
demonstrated in Paper II Figure S1. 
3.5 Chondrogenesis 
An in vitro chondrogenesis assay was applied in all three papers. In Papers I and II, the assay was used 
to evaluate the influence of LTB₄ and vitamin D respectively, while in Paper III it was used to 
ascertain the chondrogenic potential of donor-specific chondrocytes from ACI cell preparations. 
The assay is based on the formation and cultivation of cell aggregates (spheroids) as explained in 
section 3.2, followed by Alcian blue staining of spheroid sections and semi-quantitative assessment of 




and that correlates both with computerised histomorphometry and with GAG/DNA content. The 
method takes into consideration intensity and uniformity of GAG staining, cell density/matrix 
proportion and cell morphology. The Bern score provides a comprehensive evaluation compared to the 
GAG/DNA content or the simpler O’Driscoll score (153,154). Originally, the Bern score was 
developed based on Safranin O and Fast Green staining, but since the Alcian blue stianing generally 
gives more consistent results in our lab, and both stains target GAGs and proteoglycans, we have used 
Alcian blue staining in our studies.  
SCORING CATEGORIES SCORE 
A. Uniformity and darkness* of Safranin O – Fast Green stain 
No Stain 0 
Weak staining of poorly formed matrix 1 
Moderately even staining 2 
Even dark stain 3 
B. Distance between cells / amount of matrix produced 
High cell densities with no matrix in between 0 
High cell densities with little matrix in between 1 
Moderate cell density with little matrix 2 
Low cell density with moderate distance between cells and an extensive matrix 3 
C. Cell morphologies represented 
Condensed/necrotic/pycnotic bodies 0 
Spindle/fibrous 1 
Mixed spindle/fibrous with rounded chondrogenic morphology 2 
Majority rounded/chondrogenic 3 
*Sections 3‑4 µm thick 
Figure 17 Bern score. Reproduced with permission from Mary Ann Liebert, Inc., publishers: Tissue Engineering 
(152) , copyright 2006. 
3.6 Cell proliferation assay 
The xCELLigence system, based on impedance based growth measurement, provides a label-free real-
time measurement of proliferation in adherent cell cultures. The assay was used in Paper II to assess 
the influence of vitamin D on chondrocyte proliferation. Equal amount of cells are seeded in the wells 
of a microtiter plate holding electrodes at the bottom. As the cells proliferate the impedance in the 
electrodes increase, enabling real-time monitoring of cell growth represented by the cell index (CI). 
The cell index has been compared to objective measures of cell confluence and found to faithfully 
represent proliferation (155). The cells are left to adhere and equilibrate for 24 hours before any 
treatment is added. During this time, the cells can hold slightly different growth rates, which is 
accounted for by normalising the cell index to the time of treatment, resulting in a normalised cell 
index. It was further shown that the base 2 logarithm of the normalised cell index corresponds to the 





4 Summary of results 
4.1 Paper I 
The leukotriene B₄ receptors BLT1 and BLT2 were demonstrated in human articular cartilage and in 
cultured chondrocytes by immunolabelling, including the subcellular localisation to the cell membrane 
visualised by immunoelectron microscopy. In cultured chondrocytes, expression was supported by 
RT‑PCR using specific probes for the BLT1 and BLT2 receptors. The activity of receptor was 
investigated by challenging the cultured chondrocytes with LTB₄ at different concentrations (data not 
shown) and times, and a concentration of 10⁻⁸ M was sufficient to elicit phosphorylation of the 
downstream phosphor‑p44/42 mitogen‑activated protein kinase (MAPK or Erk 1/2) as detected by 
Western blotting. The density of the bands increased in a time-dependent matter and the addition of a 
specific blocker of the BLT1 receptor returned the band density to the background level. Addition of a 
specific blocker of BLT2 did not reduce the band density, while the simultaneous blocking of both 
receptors elicited the same reduction in density as blocking BLT1 alone.  
We investigated the effect of LTB₄ on growth factors, MMPs and inflammatory cytokines by 
multiplex analysis of supernatants from cultured chondrocytes treated with 10⁻¹² - 10⁻⁸ M LTB₄, and 
found that LTB₄ did not alter the secretion compared to untreated cells. Potential effect of LTB₄ on 
chondrocyte phenotype was evaluated by qPCR using probes targeting the chondrocyte signature 
genes: collagen type 1A1, collagen type 2A1, aggrecan and SOX9. The signature-gene expression 
profile was not affected by treating the chondrocytes with LTB₄. Next, we compared the relative 
expression of the BLT1 and BLT2 receptors in chondrocytes from OA samples and ACI samples and 
found that the expression level of both BLT1 and BLT2 was significantly reduced in the OA samples. 
When comparing gene expression of receptors in cartilage and cultured cells (both from OA) the 
expression of BLT1 was significantly reduced in the cultured cells compared to the native tissue, 
while the expression of BLT2 was comparable between the two groups. 
Finally, we cultured chondrocytes in spheroids to test the effect of LTB₄ on redifferentiated 
chondrocytes and cartilage-forming capability. Sections prepared from spheroids cultured in the 
presence and absence of LTB₄ at 10⁻⁸ M for 7 days were labelled with collagen type II antibody or 
stained with Alcian blue to detect glycosaminoglycans, but we found no difference between the two 
groups. 
4.2 Paper II 
The biology of vitamin D in the context of articular cartilage tissue remains uncertain. In order to 
evaluate potential effects of vitamin D on cartilage we explored the presence of the vitamin D receptor 
(VDR) in cartilage (differentiated chondrocytes), cultured chondrocytes (dedifferentiated) and 
redifferentiated 3D cultured chondrocytes. Using immunolabelling, we failed to detect the VDR in 
cartilage and redifferentiated chondrocytes, while the receptor was readily detected in cultured 
expanded chondrocytes. Further investigation of spheroids revealed that the expression of VDR was 
lost shortly after initiation of 3D cultures (48 h). Western blots showed very weak bands in 
differentiated suspension culture samples, while expression in monolayer samples was more evident. 
Relevant positive controls were included in both immunolabelling and Western blotting to verify 




The 1α‑hydroxylase enzyme that facilitates the hydroxylation of 25(OH)D to the active hormone 
1α,25(OH)₂D, was detected in cartilage (superficial layers), cultured chondrocytes and spheroids using 
immunolabelling. The finding was supported by Western blots, reproducing bands of the expected 
weight in both cartilage and cultured chondrocyte samples. PCR using primers targeting the enzyme, 
produced bands at the expected length in all differential stages. 
To verify functionality of the VDR, cultured chondrocytes were challenged with 1α,25(OH)₂D₃ at 
10⁻⁷ M or vehicle for 2 hours and labelled with VDR antibody. The treatment with 1α,25(OH)₂D₃, 
induced a translocation of the receptor from the cytoplasm to the nucleus. The activity of 
1α‑hydroxylase was demonstrated by challenging chondrocytes with increasing doses of the pro-
hormone 25(OH)D₃, which resulted in dose-dependent increase in 1α,25(OH)₂D₃ as measured in 
supernatants after 24 hours. 
To investigate the regulation of VDR and 1α‑hydroxylase during inflammatory conditions, suspension 
cultures and monolayer cultures were treated with IL1β (10 ng/mL) or 1α,25(OH)₂D₃ (10⁻⁸ M) for 24 
hours and protein levels were assessed by Western blots. Neither IL1β nor 1α,25(OH)₂D₃ influenced 
the level of VDR or 1α‑hydroxylase in suspension cultures. Likewise, the expression of 
1α-hydroxylase remained unchanged by both IL1β and 1α,25(OH)₂D₃ in monolayers. The VDR was 
however, significantly upregulated by IL1β, while the ligand had no such effect.  
Due to the low expression of the VDR in cartilage and suspension cultures, functional assays to 
explore effects of vitamin D in chondrocytes were restricted to monolayer cultures where the VDR is 
more stably expressed. Both 25(OH)D₃ and 1α,25(OH)₂D₃ increased the proliferation in the three 
donors assayed. Similarly, both 25(OH)D₃ and 1α,25(OH)₂D₃ resulted in lower expression of ACAN 
and higher expression of VCAN. Also in the chondrogenesis assay both 25(OH)D₃ and 1α,25(OH)₂D₃ 
supressed matrix production in spheroids, but only when chondrocytes were expanded in the presence 
of the pro-hormone or active hormone for one week before establishing the 3D cultures. The 
equivalent effect of 25(OH)D₃ and 1α,25(OH)₂D₃ in proliferation, gene expression and chondrogenesis 
studies further support the action of 1α-hydroxylase in chondrocytes. The active hormone had no 
effect on spheroids established from chondrocytes expanded in standard growth medium, supporting 
that the VDR is rapidly repressed in 3D cultures. 
4.3 Paper III 
Surplus chondrocytes from 17 ACI procedures were examined for their intrinsic chondrogenic 
potential in scaffold‑free 3D cultures. Chondrocytes from donors showed remarkably different 
abilities to form spheroids. The Bern score was used to quantitatively evaluate Alcian blue stained 
sections from the 17 cases followed by allocation of donors into three different groups according to 
the total score. The cell passage at the time of spheroid formation was evenly distributed between the 
groups, as were the age and gender of the patients.  
Surface receptors previously proposed as markers for chondrogenesis were analysed by flow 
cytometry. Selected surface markers comprise CD44 (hyaluronan receptor), CD106 (vascular cell 
adhesion molecule, VCAM‑1), CD146 (melanoma cell adhesion molecule, MCAM), CD166 
(activated leukocyte cell adhesion molecule, ALCAM) and CD271 (low‑affinity nerve growth factor 




and CD146 displayed donor-specific patterns regardless of group affiliation. CD271 was scarcely 
detected and only in at a low level in groups B (intermediate group) and C (worst group). None of the 
markers could be used to predict the chondrogenic capacity. 
We conducted a quantitative gene expression analysis using cells with the same passage as for the 
chondrogenesis assay. Interrogated genes included integrins α1, α2, α3, α5, α6, α10, αV, β1, β3, β4 
and β5; cell adhesion molecules CD44, CDH2 (N‑cadherin), ICAM1 (intercellular adhesion molecule 
1), MATN3 (matrillin‑3) and NCAM1 (neural cell adhesion molecule 1); and growth factor receptors 
TGFBR1, TGFBR2, TGFBR3, BMPR1A, BMPR1B and BMPR2. Comparing gene expression levels 
of group A to the expression in groups B and C revealed no significant regulation, except for TGFBR3 
that was significantly upregulated in group C samples compared to group A (best group). 
Using tandem‑mass‑tag (TMT) proteomic technology, the global spectra of cell-associated proteins 
was compared between three donors from group A and three donors from group C. By mass 
spectrometry, 2572 proteins were identified in samples from which 82 corresponded to cell-surface 
receptors. Semi-quantitative comparative analyses between the best and the worst chondrogenic 
groups revealed no significant differences in the expression of cell adhesion molecules of surface 
receptors, thus supporting the gene expression results. By setting the significance level at 0.1, a panel 
of eleven proteins were identified as differentially expressed between groups. Among the differentially 
expressed proteins, we found the subunits of the enzyme prolyl 4‑hydroxylase, an enzyme that is 






5 General discussion 
Osteoarthritis is a major cause of disability and although many mechanisms of the disease have been 
unveiled, there is still no effective treatment or cure in sight (23,75,156,157). Age, sex, joint injury, 
obesity and genetic predisposition are all considered risk factors for OA (158), and ultimately the 
disease represents the final common pathway of age‑related degenerative changes and traumatic 
injuries of synovial joints (23). A major issue is that the onset of idiopathic OA is insidious, and at the 
time of clinical presentation, the progress is too far ahead to reverse. This aspect relays specific 
demands to any treatment instituted as a preventive measure; the treatment must be safe and hold few 
or no side effects. Advanced cases of OA are successfully treated with joint replacement procedure, 
and a hip replacement can be performed even in young patients resulting in favourable long‑term 
outcomes. Due to the multidirectional movement, a replacement knee joint has a limited life span and 
the best results are obtained in patients over the age of 65 (159). This leaves a treatment gap for the 
younger patients that is only partially covered by osteotomies and cell-based procedures. With the 
increasing incidence of OA, new treatments are urgently required as the current pharmacological 
options including NSAIDs, analgesics and injections have no effect on the disease progression and at 
best serve as a temporary suspension of the pain aspect of the disease. 
The cell-based therapies introduced in the late 80’s, aimed to provide a new option for patients with 
localised cartilage defects (39,43). As of today, the array of treatments span from microfracture, via 
autologous chondrocyte implantation to implantation of chondrocytes or stem cells seeded in scaffolds 
or scaffold‑free constructs (47), all aiming to produce durable hyaline cartilage. However, no method 
has been proven superior (160,161) and the repair tissue remains interspaced by fibrocartilage. 
Clinical studies point to a common challenge; some patients respond worse to the treatment than 
others and being able to recognise factors associated with an inferior outcome could guide the quest 
for a more optimal treatment for these patients. Studies of patient characteristics largely agree on age, 
female gender and previous surgery as negative predictive factors (162,163). While some attempts 
have been made to identify biomarkers useful for stratification, few reliable or accessible markers 
have been identified (97,164–166).  
Overall, the progression of the field is largely based on trial-error approaches and no significant 
advancements has been made during the last decade. Both in the case of OA and in the case of 
localised cartilage damage, it is of paramount importance to expand the understanding of the 
biological principles governing tissue homeostasis in order to acquire durable treatments. In this 
thesis, we have tried to gather new knowledge on the biology of cell signalling receptors that have 
been little studied in the context of cartilage and OA. Furthermore, we have explored the link between 
cell-surface receptors expression and chondrogenesis as a potential tool to select patients more likely 
to obtain a favourable outcome of cell-based therapies. 
5.1 Paper I 
NSAIDs are commonly prescribed to OA patients for pain management. Side effects in the 
gastrointestinal tract are well known, but the COX inhibition also leads to shunting from the 
prostaglandin-axis to the leukotriene-axis (167). Studies have suggested that the leukotrienes are 
important in modulating inflammatory joint diseases as the deletion of leukotriene-receptors halts the 




LTB₄ in inflammatory joint disease include elevated levels of LTB₄ in the joint fluid (168) and the 
expression of the high- and low affinity receptors (BLT1 and BLT2) in synovial tissue of OA and RA 
patients (169). LTB₄ has also been shown to regulate the synthesis of proinflammatory cytokines and 
MMPs in OA synovial membrane and chondrocytes (56).  
Although the main recognised function of LTB₄ is recruitment and activation of leukocytes (170), 
which may be the main mechanism of the protective effect of BLT1/BLT2 knockout in mouse RA 
models (68), a direct influence on joint tissues is plausible. In rat myoblasts, LTB₄ promoted 
proliferation and differentiation via BLT1 (171), contributing to muscle regeneration after injury. Both 
receptors are expressed in normal and OA subchondral osteoblasts (172) where they are involved in 
increased osteocalcin secretion associated with OA subchondral bone remodelling. Studies on OA 
chondrocytes indicate that the secretion of LTB₄ increase when COX‑inhibitors are added to the 
culture (53), meriting further investigation of the influence of the LTB₄ system on chondrocytes.  
Despite reports on chondrocytes expressing the 5-LOX and FLAP enzymes, which are necessary to 
synthesise LTB₄, and some potential effects on LTB₄ on chondrocyte functions (56), there are no 
previous reports on the LTB₄ receptors expression in human chondrocytes. In Paper I, we present 
novel data on both the high-affinity BLT1 receptor and the low-affinity BLT2 receptor being 
expressed in human cartilage and chondrocytes. In order to ascertain the role of these receptors we 
investigated readouts relevant to inflammation and cartilage biology. We were however, not able to 
confirm the upregulation of MMP-1 upon LTB₄ treatment of chondrocytes, which could be explained 
by the different time-frames of the treatments or different sensitivity of the assays (56). Jacob et al. 
described a favourable effect of the COX-2 dependent prostaglandin F₂α on both chondrogenesis and 
cartilage gene expression profile of the pellet cultures (173). We found no such effect of LTB₄ on 
chondrogenesis or gene expression profile, which can be explained by experimental differences, or 
that the lipid mediators are not comparable in this regard. The role of LTB₄ receptors in cartilage 
biology is thus still elusive and the protective effects of BLT1 or BLT2 knockout in murine studies, or 
effects of dual COX/5-LOX inhibition is most likely mediated through effects on the synovium and 
not cartilage. 
A potential role of the receptors in cartilage, which was not framed by our experimental setting, is 
during fracture healing as suggested from studies showing that BLT1 is expressed in fracture callous 
chondrocytes (174). The currently available studies are restricted to murine experiments where LTB₄ 
production is limited through knockout of the 5-LOX or treatment with 5-LOX inhibitors, resulting in 
improved callous formation during early fracture healing (174,175). A recent study on mice 
investigating lipid mediators in callus after fracture reveal a rapid decline in LTB₄, suggesting a role of 
leukotrienes in mitigating the inflammatory response (176). 
5.2 Paper II 
Another molecule receiving attention in OA research is vitamin D. The role of vitamin D in regulation 
of bone health and serum calcium/phosphorous level is well described (177). The reason for the 
interest of vitamin D in the setting of OA originate from the discovery of extrarenal 1α‑hydroxylase 
activity in inflammatory diseases like sarcoidosis, inflammatory bowel disease and rheumatoid 
arthritis (83,178), along with the notion of OA patients exhibiting a higher prevalence of vitamin D 




supported by a proposed relationship between vitamin D deficiency, low bone mineral density and OA 
(183,184), and an association to OA subchondral bone changes has been suggested (73,185). Since 
vitamin D has a low risk profile, it would be ethically acceptable to advise vitamin D supplementation 
as a preventive measure of OA development, given that a beneficial effect can be documented (26). 
Thus, great expectations have been placed in studies where OA patients were prescribed vitamin D 
supplementation, hoping to slow down the disease progression. Although pilot studies pointed to 
improved pain and function scores from vitamin D supplementation (75), the latest randomised trials 
found no effect of vitamin D supplementation on pain, function or cartilage volume (77,186). A recent 
review points to the heterogeneous and confusing outcomes in registry studies on vitamin D and 
osteoarthritis and highlight the lack of studies investigating vitamin D effects on articular cartilage 
degeneration and regeneration (187). As several external factors, like diet and sun exposure, are 
difficult to control for in observational studies, there is a need of in vitro experiments where these 
factors can be controlled. 
Low amounts of  VDR and 1α-hydroxylase have been reported in murine growth plate chondrocytes 
(188,189), while a handful of studies report on the expression of vitamin D receptor (VDR) in human 
OA and RA cartilage, and during chondrocyte culturing (81,82). The VDR seems to be absent or very 
modestly expressed in normal adult cartilage (123). During OA or RA development, and in 
hypertrophic chondrocytes, the receptor is detected (123,190). While 1α,25(OH)₂D₃ treatment of 
chondrocyte cultures is reported to increase secretion of MMP-1, -3, and -13 (190,191), the opposite is 
seen in synovial stromal cells (192) indicating a dual effect on joint tissues. 
Since reports on VDR expression in cartilage tissue have been divergent (82,123), our initial efforts 
focused on studying the expression in our material. Only two previous reports from one group have 
reported on VDR expression in OA cartilage, and we have found no further studies from that group 
regarding this subject. The lack of staining of our OA tissue may be due to a random effect as our 
experiments were limited to four cartilage samples, that the chondrocytes in our samples were not in a 
hypertrophic state or that the VDR is absent or expressed below the detection threshold of our assay. 
Contrary to previous reports, we did not detect a regulatory effect of 1α,25(OH)₂D₃ on VDR gene- or 
protein expression (188,190), which could be explained by different timeframes of the experiments. 
We did however note that VDR expression increased upon treatment with IL-1β. Adding to the 
existing knowledge, we show that the receptor expression is rapidly repressed upon cell condensation 
with no staining of VDR already after 2 days of 3D culturing, illustrating that the expression of VDR 
relies on the differential status of the chondrocyte. 
An autocrine/paracrine effect of vitamin D on cartilage would require the chondrocyte to exhibit 
1α‑hydroxylase activity as previously described in rat chondrocytes (188) and in human osteoblasts 
and synovial fluid macrophages (193,194). In Paper II, we provide novel evidence of 1α-hydroxylase 
expression in human cartilage, cultured chondrocytes and spheroids. The enzyme activity was 
supported by a dose-dependent increase in 1α,25(OH)₂D₃ levels in chondrocyte supernatants following 
treatment with 25(OH)D₃, as previously described in human osteoblasts (86). 
Both 25(OH)D₃ and 1α,25(OH)₂D₃ have been shown to inhibit proliferation and induce differentiation 
in human osteoblasts (86), while proliferation of synovial stromal cells was inhibited by 1α,25(OH)₂D₃ 




proliferation rates in chondrocytes, and had an unfavourable effect on the expression of matrix-
associated genes. We also found that both 25(OH)D₃ and 1α,25(OH)₂D₃ treatment in adherent cultures, 
decreased matrix production during chondrogenesis, which is not surprising given that vitamin D can 
be used to induce osteogenic differentiation (195). Considering the results from the recent studies on 
other joint tissues, vitamin D seems to have different effects on osteoblasts, synovial tissue and 
cartilage. Overall, it may be that vitamin D exert favourable effects in healthy stages, where receptor 
expression in cartilage is low or absent, while during disease conditions the effect on cartilage could 
be unfavourable.   
5.3 Paper III 
Patients that have suffered a localised cartilage injury or disease with subsequent debilitated knee 
joints can benefit from cell-based therapies that aim to repair the cartilage defect and prevent 
secondary OA. However, long term follow-up studies after ACI or microfracture indicate that up to 
40% require further surgical treatment (161). Such observations indicate that cell-based therapies seem 
to benefit only a subset of patients. Through many years of in vitro studies with surplus ACI cells, we 
have observed that chondrocytes from different donors display different potentials to form spheroids. 
Donor to donor variation, and even variation between single cell clones from the same donor in 
chondrogenesis, has also been described by others (97). Both the hanging-drop and the pellet 
approaches to induce chondrogenesis rely on initial cell condensation. We therefore hypothesised that 
cell-surface receptor expression is of paramount relevance for chondrogenesis and that expression 
levels of these molecules could be used to select donors with increased chondrogenic potential. Based 
on previous publications, we selected a range of cell-surface markers, integrins, cell adhesion 
molecules and growth factor receptors that may be differentially expressed according to different 
chondrogenic abilities (97,109,196,197).  
We utilised the Bern score to sort out donors displaying different chondrogenic abilities. The score has 
previously been used to compare chondrogenic capacity between different cell types (198,199), while 
the comparison of chondrogenesis in chondrocytes has been restricted to GAG measurements (97). 
The Bern score has been validated and found to correlate with GAG measurements in chondrocyte 
pellet cultures (152). In clinical studies, others have compared the expression of surface markers in 
transplanted cells with clinical outcomes (164). However, it is still unsolved whether the chondrogenic 
potency of cells, as checked in in vitro settings, correlates with clinical outcomes, and thus the 
extrapolation of results should be taken cautiously. From all the tested genes, the TGFBR3 transcript 
was the only marker differentially expressed between groups and inversely correlated with 
chondrogenic potential. This observation was unexpected and goes against previous observations on 
chondrogenesis in other cell systems (200,201). We did not validate our finding at the protein level 
and thus, interpretation of this result should be done with care. 
Our study was designed in a similar way to the study of Grogan et al. (97), thus we were expecting to 
find comparable results in regards to the surface receptors that were investigated in both studies. The 
lack of confirmation by our study may be explained by the different cartilage sources as Grogan et al. 
used chondrocytes from autopsies. Furthermore, Grogan et al. divided their samples in two groups 
based on GAG measurements, although they published the paper on the Bern score one year ahead. 
Our results are thus more in line with the findings of Stenberg et al. (164) who detected no correlation 




Since the selected cell surface markers did not reveal any predictive value, we proceeded with a global 
protein analysis. Quantitative proteomics confirmed the results from gene expression since none of the 
selected cell surface markers were differentially expressed. Setting the significance level at 0.1, we 
found that the expression of the subunits of prolyl 4‑hydroxylase, the enzyme that catalyse the 
formation of 4‑hydroxyproline, a vital element in the triple helix formation of collagen (202), were 
upregulated in chondrocytes of high chondrogenic potential. In a previous study on chondrogenesis, 
the gene expression of the beta subunit was upregulated (203). Given its relevance in collagen 
biosynthesis, it is likely that this molecule represents a true biomarker of chondrogenic potential. 
However, since this is the result of a high-throughput assay, the findings needs to be validated by 
specific protein- and gene expression studies. 
If future studies are able to detect molecular markers capable of stratifying patients that may have 
greater benefit of cell-based therapies, we are left with the question on how to utilise these markers. 
From a clinical point of view, having to decide the treatment based on cells harvested from cartilage 
biopsies is far more advanced and implies an extra procedure to the joint than measuring molecular 
markers in blood or even in synovial fluid. In recent efforts, a few markers with predictive potential in 
the clinics have been identified in synovial fluid samples (165,166). Probably, a combination of 
biomarkers with clinical characteristics of patients is perhaps the most viable option in regards to 
patient stratification.  
As far as we know, no study has investigated whether chondrogenic potential in vitro is predicative of 
a favourable clinical outcome of ACI. To complement the knowledge gained in Paper III, we have 
recently obtained permission to compare the results of this in vitro study with the two‑year follow-up 
clinical outcomes of patients from which the surplus chondrocytes were originally derived. This will 






6 Conclusion and implications 
6.1 Paper I 
In Paper I, we demonstrated that human articular chondrocytes express functional LTB₄ receptors and 
are thus susceptible for input in case of elevated levels of LTB₄ from inflammation or shunting after 
blocking the COX enzyme. We were however, not able to identify effects on chondrocyte biological 
functions in vitro as assessed by matrix production in spheroid cultures, regulation of cartilage 
signature gene expression and the release of matrix degrading enzymes or inflammatory cytokines. 
The LTB₄ axis has been suggested as a key player in inflammatory joint disease, and its direct effect 
on the recruitment of immune cells could play a major role, whereas direct LTB₄ effects on the 
cartilage tissue is less relevant. The role of LTB₄ receptors in cartilage thus remains elusive, although 
a recent report suggest that leukotrienes may hold an important role in the callous chondrocyte by 
resolving inflammation during early fracture healing.  
6.2 Paper II 
In Paper II, expression of VDR in cartilage at the protein level was elusive, but upregulated upon 
expansion in monolayer cell culture, and further enhanced under inflammatory conditions. In 
monolayer cultures both 25(OH)D₃ and 1α,25(OH)₂D₃ induced enhanced proliferation while the 
effects on cartilage signature genes was unfavourable. The gene expression results were supported by 
the observations in chondrogenesis assay where GAG deposition and matrix production was decreased 
in chondrocytes treated with 25(OH)D₃ or 1α,25(OH)₂D₃. We provide novel evidence of 
1α‑hydroxylase activity in chondrocytes, which could imply that chondrocytes contribute to the 
increased level of active hormone found in the synovial fluid of patients with inflammatory joint 
diseases. The overall impact of vitamin D on the chondrocyte seems to be less favourable in terms of 
cartilage healing. However, since the expression of receptors depends on differentiation status of the 
chondrocyte, the observed effects are probably more relevant in the diseased or inflamed joint. 
6.3 Paper III 
In paper III, we established that surplus chondrocytes of patients undergoing ACI have diverging 
potential of forming cartilage in vitro. Our data indicate that cell‑surface molecules such as integrins 
and other cell adhesion receptors are not good predictors of the chondrogenic potential. 
High-throughput proteomic analyses uncover the prolyl 4‑hydroxylase enzyme as a potential 
biomarker worth investigating in future studies along with the TGF‑β receptor superfamily. In the near 
future, we plan to augment the data with the clinical outcomes of the ACI, which will enable us to 
investigate the correlation between clinical outcome and chondrogenesis. It has not been established 
yet if the chondrogenic potential of patient-derived chondrocytes in vitro correlates with clinical 
outcomes. We hope to clarify this matter in a future study where the data presented here are linked to 
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